PATH is pleased to launch the Advocacy Pack for Subcutaneous DMPA, a comprehensive suite of evidence-based tools that advocates can use to help increase access to a new type of injectable in their countries.
Subcutaneous DMPA (DMPA-SC) is an innovative, easy-to-use injectable that is administered under the skin. It has the potential to dramatically increase contraceptive access by enabling community health workers to provide injections and even women to self-inject. DMPA-SC is currently being introduced or scaled in Family Planning 2020 (FP2020) countries as Pfizer’s branded product Sayana® Press.
The Advocacy Pack for Subcutaneous DMPA equips advocates with information, data, and tools to advance policy change and mobilize resources to support expanded access to this method, as part of a wide range of contraceptive options.
Advocacy pack highlights:
- Available in English and French on the Reproductive Health Supplies Coalition website.
- Consists of 15 tools to inform advocacy and communications planning and to support direct advocacy with decision-makers.
- Based on the latest evidence on DMPA-SC.
- Packaged as unbranded, customizable materials for country advocates and stakeholders.
Three ways to take action today:
- Download and use the Advocacy Pack for Subcutaneous DMPA in your family planning advocacy.
- Forward this email to your colleagues, especially those in FP2020 countries.
- Spread the word on social media with this easy retweet: https://twitter.com/PATHadvocacy/status/865087336979337216
Thank you for your efforts to increase contraceptive access and choice for women and adolescent girls worldwide! Please send any questions or comments about these new resources to [email protected].
The Advocacy Pack for Subcutaneous DMPA was developed by PATH in collaboration with international and national family planning organizations. Capital for Good, a grant recipient of the Bill & Melinda Gates Foundation, provided generous support for this project.
Cliquez pour en savoir plus